Article Text

Download PDFPDF

Basic science: Cardiovascular disease basic research
e0046 Rosiglitazone attenuates myocardial remodelling in spontaneously hypertensive rats
  1. Ti Yun,
  2. Hao Ming-Xiu,
  3. Li Chuan-Bao,
  4. Wang Zhi-Hao,
  5. Hou Xiao-Yang,
  6. Liu Jun-Ni,
  7. Zhang Wei,
  8. Zhang Yun
  1. Shandong University Qilu Hospital


Background Rosiglitazone, an important Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, improves left ventricular hypertrophy in diet-induced hypercholesterolemic rats. However, the effects of rosiglitazone on cardiac remodelling in spontaneous hypertension rats are unclear.

Methods 20 male 8-week-old SHRs were randomly divided into two groups: one treated with oral saline (n=10) and the other treated with rosiglitazone (5 mg/kg/d) (n=10), compared with ten age-matched Wistar-Kyoto (WKY) rats as a control group. Echocardiography, immunohistochemistry, real-time RT-PCR, co-immunoprecipitation, and Western blot analysis were performed to assess the effects of rosiglitazone.

Results After 16 weeks of treatment, rosiglitazone decreased left ventricular weight (LVW) to body weight (BW) ratio (2.35±0.11 vs 2.56±0.14 mg/g, p<0.01). According to echocardiography, thickening of interventricular septum and posterior wall was prevented (2.07±0.03 vs 2.15±0.04 mm, p<0.01; 2.08±0.05 vs 2.15±0.05 mm, p<0.01, respectively) and midwall fractional shortening (MFS) was improved (23.82±0.23% vs 23.33±0.4%, p<0.01) by rosiglitazone. Rosiglitazone decreased collagen I and III mRNA expression (0.06±0.01 vs 0.18±0.01, p<0.01; 0.05±0.01 vs 0.13±0.01, p<0.01, respectively), and normalised the MMP-9/TIMP-1 ratio (1.16±0.12 vs 0.78±0.18, p<0.01). Furthermore, AP-1 activation (0.51±0.10 vs 0.71±0.09, p<0.01) and NF-κB expression (0.33±0.04 vs 0.45±0.08, p<0.01) were suppressed in treated group.

Conclusion These results suggest that treatment with rosiglitazone will improve myocardial remodelling in hypertension. Taken together, PPAR-γ agonist rosiglitazone may exert a protective effect on cardiac remodelling in SHRs by decreasing the expression of AP-1 and NF-κB.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.